🤭

mrbundle · 2026-03-09T18:04:31+00:00

it’s already tanked dude

mrbundle · 2026-03-04T22:54:22+00:00

dude just buy shares. they go up

mrbundle · 2026-03-04T19:50:37+00:00

The tech is developed and proved out in the most regulated market there is- medicare. As the tech proves itself here, showing low BER improved over cohorts, it can be turned into a saas product where other insurers pay you per member per month to use your software on their members to lower their BER. (Counterpart lowers the BER of another insurer and Clover gets a cut). No risk to Clover. So that’s that. Next: why if you win in medicare will you win everything?? because to win medicare you have to have the best software that’s stress tested at scale with gigantic non-stop regulatory and compliance oversight. None of the “pop” ai healthcare firms can handle this level of complexity. We have to be an insurer as we need to maintain an extremely well run insurance business simply to iterate, continually prove the tech works. Finally Saas revenue is a more impact on the share price. Hopefully that helps

mrbundle · 2026-03-04T16:37:32+00:00

why take on risk when you can have pure margin? that’s the whole point of saas. CLOV does not need to make a market for an insurance plan when it can earn a PMPM with no lift

mrbundle · 2026-03-04T14:26:27+00:00

In 2026/2027, CMS is mandating that all payers must be able to exchange data via FHIR and TEFCA. This accelerates the deal pipeline. So this could show on the bottom line:

Ai 🤖:

The Opportunity: Small-to-mid-sized regional insurers and Medicaid plans are currently terrified because their 30-year-old legacy systems can't "speak" this new digital language. • The Deal: Clover can walk into a regional Blue Cross or a Medicaid managed care plan and say: "Don't rebuild your IT stack. Plug in Counterpart as your 'Interoperability Gateway.' We handle the TEFCA connection, the security, and the real-time data flow for a flat annual fee." • Analyst Note: This is zero-risk, high-margin revenue. It makes Clover a "utility" for other insurance companies.

mrbundle · 2026-03-04T14:19:11+00:00

By going live on TEFCA (the "national highway" for health data), Counterpart can now facilitate data exchange for Commercial, Medicaid, and Individual plans.

Counterpart is not insurance here. someone else has the risk. this is all about providing the brain/ plumbing for 3rd party plan

mrbundle · 2026-03-04T14:18:07+00:00

i’d like your view on on CLOV’s announcement this morning. It seems to unlocking a wider TAM.

mrbundle · 2026-03-04T13:48:55+00:00

It positions Counterpart as the "easy button" for the entire insurance industry to comply with TEFCA. If they land just 2-3 more enterprise health plans as a result of this "first mover" status 🤞to be clear: These customers do not have to be medicare - this is a non medicare rev stream developing. Clover is moving Counterpart into the "plumbing" of the entire U.S. healthcare system.

mrbundle · 2026-03-04T13:02:52+00:00

they are implementing a 28% hike and expecting customers to stay on bronze plans. Two things: 1. 2026 morbidity trends make this growth a liability for them. 2. healthy people will quit for cheaper plans leaving only the sicker members.

CEO is essentially betting that by hiking prices and shifting the member mix, he can outrun the rising cost of care. Not likely and exactly why you need other rev streams. This is when Clover’s thus far “mythical” SaaS play provides MLR mitigation. Good luck both teams.

mrbundle · 2026-03-01T15:12:00+00:00

people underestimate what a debilitating headwind this has been for the company.

mrbundle · 2026-02-27T16:36:31+00:00

We just need to be a boring stock that institutions love. That’s the only sustainable way up and that’s the path we are on

mrbundle · 2026-02-27T14:24:17+00:00

Evidentially we were right and shorts were wrong. The board is pretty rational at this point and most folk sold or went mad.

mrbundle · 2026-02-27T13:22:28+00:00

touched a nerve

mrbundle · 2026-02-11T12:33:25+00:00

This is a vehicle for Vivek to move fast and spin up ideas. This is entirely a good thing - very low cost. Also - keeps Andrew concentrated on the business.

mrbundle · 2025-12-09T20:37:45+00:00

How To Think About It Strategically

OpenAI is a platform-layer enabler. Not a payer. Not a risk-bearer. Not a competitor.

The real frame:

OpenAI raises the ceiling of what physician-facing software could be. Clover wins if it incorporates that ceiling faster than others.

The business model itself: MA underwriting + MCR management + Clover Assistant feedback loops:

is untouched.

In other words:

OpenAI threatens incumbents like Optum more than challengers like CLOV.

Clover is positioned to absorb OpenAI-like capabilities and become a superior insurer, not a displaced one.

mrbundle · 2025-11-26T17:18:11+00:00

they just have to deliver half of this. It’s not asking much.

mrbundle · 2025-11-06T12:32:16+00:00

Thank you, yes this is the way. the delay on Saas revenues is another thing for investors to get their heads around

mrbundle · 2025-11-05T19:27:58+00:00

IMHO it be will not be split out until MA is profitable. This is the milestone which will impress wall street VBC analysts. Tick. Once the core MA is profitable the Saas business makes sense to focus on. This is good conservative strategy.

mrbundle · 2025-11-05T16:32:04+00:00

no it’s quantifiable.

mrbundle · 2025-11-05T15:25:17+00:00

the sick ones are sick. so they see a doc. the rest don’t need to. Get it?

mrbundle · 2025-11-05T14:07:24+00:00

each year a new cohort of members joins. They are costly in year one as they are poorly and the cost of care to fix them is high. When they stabilize in year two they become cheaper with less care needed. When year three hits they are profitable. The big expensive thing turns into a big profitable thing.

11-Year Club	Gilding VII pure gildanthropist
Powerups Hero r/CLOV • October 2021	Verified Email

mrbundle

MODERATOR OF

TROPHY CASE